Ftse Mib
38.655,30
1,73%
DAX
22.986,82
2,01%
S&P 500
5.638,94
2,13%
NASDAQ
17.754,09
2,61%
Bitcoin
84.305,29
0,41%
Pepperstone
Advertisement
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Alterity Therapeutics Limited (ATHE) Alterity Therapeutics Limited (ATHE) Notizie

Alterity Therapeutics Limited

ATHE
3,94
0,16 (4,23%)
15 Mar 2025 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Ricevuta di Deposito
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
14/3/202512:32EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14/3/202511:50EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
10/2/202513:25GLOBEAlterity Therapeutics Raises A$40.0 million in Placement
06/2/202514:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06/2/202514:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/2/202512:33EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04/2/202514:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
30/1/202514:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
30/1/202514:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
30/1/202513:35GLOBEAlterity Therapeutics Announces Positive ATH434 Phase 2..
24/1/202513:35GLOBEAppendix 4C – Q2 FY25 Quarterly Cash Flow Report
09/1/202513:25GLOBEAlterity Therapeutics Issues Shareholder Letter Highlighting..
06/1/202514:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04/12/202413:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04/12/202413:35GLOBEAlterity Therapeutics Completes Last Patient Visit in..
22/11/202413:14EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
22/11/202413:10EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
22/11/202412:58EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
19/11/202414:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
19/11/202413:25GLOBEAlterity Therapeutics Appoints Abby Macnish Niven as Company..
12/11/202413:35GLOBEAlterity Therapeutics Announces Presentation on Tracking the..
12/11/202412:27EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06/11/202413:35GLOBEAlterity Therapeutics Announces New Publication Describing..
31/10/202412:35GLOBEAppendix 4C – Q1 FY25 Quarterly Cash Flow Report
14/10/202413:35GLOBEAlterity Therapeutics to Participate in a Fireside Chat at..
11/10/202413:35GLOBEAlterity Therapeutics Announces Presentation of New Data..
02/10/202413:35GLOBEAlterity Therapeutics Raises Profile with Multiple Data..
30/9/202413:35GLOBEAlterity Therapeutics Appoints Abby Macnish Niven as Chief..
23/9/202414:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
23/9/202413:35GLOBEAlterity Therapeutics to Deliver Multiple Oral and Poster..
29/8/202412:07EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
31/7/202413:35GLOBEAppendix 4C – Q4 FY24 Quarterly Cash Flow Report
31/7/202412:23EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
24/7/202413:35GLOBEAlterity Therapeutics to Present at MST Financial Webinar
17/7/202413:35GLOBEAlterity Therapeutics Reports Positive Interim Data from..
17/7/202413:25GLOBEAlterity Therapeutics Reports Positive Interim Data from..
13/6/202414:28EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
13/6/202401:22GLOBEAlterity Therapeutics to Present at the MST Access ‘Hidden..
30/5/202401:21GLOBEAlterity Therapeutics to Host Webcast Today on New Data from..
08/5/202413:25GLOBEAlterity Therapeutics Phase 2 Data Monitoring Committee..
30/4/202413:25GLOBEAppendix 4C – Q3 FY24 Quarterly Cash Flow Report
29/4/202413:25GLOBEAlterity Therapeutics Presents New Data Demonstrating..
17/4/202413:25GLOBEAlterity Therapeutics Parkinson’s Disease and Multiple..
10/4/202413:25GLOBEAlterity Therapeutics to Present New Data on ATH434 at the..
26/3/202415:25GLOBEAlterity Therapeutics Receives a A$3.9 Million Research &..
Apertura: 3,80 Min: 3,80 Max: 4,01
Chiusura: 3,78

La tua Cronologia

NASDAQ
ATHE
Alterity Therapeutics
LSE
0OO6
Centrum Nowoczesnych Tec...
COIN
KSMKRW
Kusama
USOTC
AWLRF
Awale Resources (PK)
LSE
JARU
Jpmorgan Global Core Rea...
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci